Streamlining the CAR T cell therapy workflow: A look into closed and semi-automated processes

In this application note, Cytiva outlines a CAR T cell manufacturing workflow, addressing challenges associated with the complex and costly manufacturing process of T cell immunotherapies. The described semi-automated, closed CAR T process is designed for commercial production, achieving a substantial expansion of T cells (1 × 10¹⁰) with high transduction efficiency (greater than 80% eGFP) over an 8-day manufacturing period. This approach aims to enhance the feasibility and efficiency of CAR T cell production for widespread clinical applications.